Top Markets
#1 Islamic Coin Islamic Coin +151.45%
#2 DOVU DOVU +49.92%
#3 Velvet Velvet +43.90%
#4 Black Phoenix Black Phoenix +34.98%
#5 Fake World Assets Fake World Assets +19.35%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.99%
#7 DoubleZero DoubleZero +18.67%
#8 Akedo Akedo +18.04%
#9 HOME HOME +14.34%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +13.01%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
InVivo Therapeutics Holdings Corporation InVivo Therapeutics Holdings Corporation

InVivo Therapeutics Holdings Corporation

NVIV
Rank in Stocks #39771
InVivo Therapeutics Holdings Corp. is a biotechnology and biomaterials firm,... InVivo Therapeutics Holdings Corp. is a biotechnology and biomaterials firm, actively involved in research and clinical development. The company specializes in creating and bringing to market innovative biopolymer scaffolding devices designed to address spinal cord injuries (SCI). Its primary investigational product is the Neuro-Spinal Scaffold implant, a bioresorbable polymer scaffold. This device is engineered to be implanted directly at the site of injury within the spinal cord, aiming to treat acute SCI. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Share Price
$0.26
Last synced: 2024-03-11
Market Cap
$356.29K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade InVivo Therapeutics Holdings Corporation (NVIV)

Category

Healthcare
Revenue for InVivo Therapeutics Holdings Corporation (NVIV)
Revenue in Aug 2026 TTM: 0
According to InVivo Therapeutics Holdings Corporation latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for InVivo Therapeutics Holdings Corporation from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE